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ABSTRACT
Introduction: Tuberculosis (TB) is a serious public
health problem in many parts of the world. Strategies
to curb the spread of TB must match the multifaceted
nature of the epidemic. The use of mass media is one
of the important strategies in communicating
behavioural change in relation to TB prevention and the
treatment. However, the benefits of this intervention are
unclear. We, therefore, plan to conduct a systematic
review on the effects of mass media interventions on
TB awareness, health-seeking behaviour and health
service utilisation.
Methods and analysis: We will preferably include
randomised controlled trials (RCTs) in this systematic
review. However, non-randomised studies will be
included if there is an inadequate number of RCTs. We
will perform electronic searches in PubMed, Scopus and
other databases, along with manual searches. Articles
written (or translated) in English and French and
published between 1 January 1980 and 31 October
2013 will be eligible for inclusion in this review. The
primary outcomes will be TB knowledge, attitudes and
awareness, healthcare-seeking behaviour and service
utilisation. The secondary outcomes will include stigma
and discrimination against people with TB and the costs
of the interventions. We will investigate clinical and
statistical heterogeneity and pool studies judged to be
clinically and statistically homogeneous. Relative risks
will be calculated for dichotomous outcomes and mean
differences for continuous outcomes, both with their
corresponding 95% CIs.
Ethics and dissemination: The systematic review will
use data that is not linked to individuals. The review
findings may have implications for clinical practice and
future research, and will be disseminated electronically
and in print through peer-reviewed publications.
Protocol registration number: PROSPERO
CRD42013005867
INTRODUCTION
Although there have been advances in the
screening, diagnosis and treatment methods
for the tuberculosis (TB) disease since
Mycobacterium tuberculosis was ﬁrst discovered,
TB remains a serious public health problem
in many parts of the world. Globally, there
were an estimated 8.7 million new TB cases,
and 1.4 million deaths from TB in 2011.1
The largest number of new cases of TB
occurred in 22 low-income and middle-income
countries, accounting for 80% of new cases
globally in 2011.1
Directly observed treatment short course
(DOTS) is the WHO recommended strategy
for treating TB. However, the treatment
alone is not sufﬁcient to curb the spread of
TB. Evidence suggests that cultural, environ-
mental and politicoeconomic factors are
important determinants of access to and use
of TB services2, and so addressing the bar-
riers to patients’ access to and use of services
can potentially turn the tide of the global TB
epidemic. Therefore, strategies that promote
early case detection and treatment adher-
ence; raising awareness about TB, reducing
stigma, discrimination and delayed TB diag-
nosis or treatment as well as empowering
people affected by TB and mobilising polit-
ical commitment and resources for TB are
Strengths and limitations of this study
▪ To our knowledge, this is the first systematic
review protocol that will attempt to assess the
impact of mass media interventions on tubercu-
losis awareness, health-seeking behaviour and
health service utilisation.
▪ This study will help guide clinical practice and
inform future studies on the most effective
media platforms to use.
▪ Non-randomised studies with a high risk of bias
and of low-quality evidence may be this study’s
limitation. We will, however, investigate the
robustness of the results to risk of bias by
excluding studies with a high risk of bias.
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important to curb the spread of TB.3 The advocacy,
communication and social mobilisation (ACSM) activ-
ities recommended by the WHO is one such strategy.3
However, ASCM activities are most effective when deliv-
ered in combination and not separately.3
Mass media campaigns are widely used to disseminate
information to vast audiences through the use of media,
such as television, radio, newspapers, Internet, books,
posters and billboards. They can play an important role
in ACSM activities. Media advocacy involves using mass
media in communicating TB-related health information
to the public so as to raise awareness on TB-related
issues and problems.3 The mass media campaigns may
also be used to convey behaviour-change messages that
aim to change the publics’ knowledge, attitudes and
practices.3
Mass media interventions have proven effectiveness in
changing individuals’ behaviour4–8 and healthcare util-
isation9, reducing stigma10 and raising awareness of the
signs and symptoms of other diseases.11 With respect to
TB, mass media interventions have the potential to assist
in generating knowledge about TB, promoting aware-
ness on the services that exist for TB diagnosis, preven-
tion and treatment to assist with early diagnosis,
treatment compliance and stigma reduction.
However, while systematic reviews on the impact of
mass media interventions for promoting HIV testing,4 5
smoking prevention,6 healthcare utilisation9 and redu-
cing mental health-related stigma10 have already been
undertaken, there are no systematic reviews of the
impact of mass media interventions in TB management.
We, therefore, plan to conduct a systematic review on
the impact of mass media interventions on TB aware-
ness, health-seeking behaviour and health service utilisa-
tion. A secondary aim is to examine the impact of mass
media interventions on stigma and discrimination.
METHODS AND ANALYSIS
Criteria for considering studies for review
Types of studies
We will include randomised controlled trials (RCTs).
However, non-randomised studies will be considered if
there are inadequate number of RCTs (ie, less than
ﬁve). We will include the following types of non-
randomised studies:
Non-RCTS;
Controlled before and after studies (CBA);
Interrupted time series studies (ITS), that is, studies in
which there are at least three points of data collection
before and after the intervention and the intervention
occurs at a clearly deﬁned time point;
Prospective cohort studies;
Retrospective cohort studies if baseline exposure data
were collected at the time of baseline of the study.
The aforementioned studies may be useful in evaluat-
ing the effects of the mass media interventions when it
is difﬁcult to randomise.
Uncontrolled before and after studies will not be
included in the review because secular trends or sudden
attributes will make it difﬁcult to attribute the observed
changes to the mass media intervention.12 We will also
exclude uncontrolled studies with postintervention mea-
surements but no baseline measurements.
Types of participants
Participants will be the general public, speciﬁc target
groups (people living with HIV, healthcare workers, mine
workers, prisoners, pregnant women, multidrug-resistant
(MDR) TB suspects, household contacts of conﬁrmed
patients with TB and people with risk factors such as dia-
betes, smoking, alcohol or drug use) and patients with
TB. These participants will be from all age groups (chil-
dren and adults).
Types of interventions
Mass media interventions use a range of methods to
communicate a message to the general public or speciﬁc
groups. The media include radio, television, internet,
mobile phone, print (newspapers, magazines, booklets,
leaﬂets, posters and pamphlets), ﬁlms, documentaries,
billboards, folk media-like street dramas or a combin-
ation of these. For the proposed systematic review, we
will include studies that report on any mass media inter-
vention aimed to either raise TB awareness and knowl-
edge levels or raise health service utilisation rates or
other health-seeking behaviour or reduce stigma and
discrimination levels and delivered in formats seeking to
meet the needs of the general and speciﬁc target audi-
ences (see participants above).
We will exclude interventions based on scientiﬁc
media such as professional journals, leaﬂets and book-
lets speciﬁcally targeted to healthcare workers. We will
also exclude interventions based on the use of media
such as video, booklets and leaﬂets in a healthcare
setting for individual patient information purposes. We
will exclude studies of mass media interventions that
have only been reported in terms of secondary out-
comes. Lastly, we will exclude mass media interventions
coupled with other interventions because it will be difﬁ-
cult to separate out the effects of the multiple interven-
tions occurring simultaneously.
The comparison will be no intervention, preinterven-
tion waiting list control or an alternative intervention.
Types of outcome measures
Primary outcome
The primary outcomes in this review are:
Changes in knowledge, attitudes, awareness and opi-
nions about TB and health-seeking behaviour inten-
tions for TB.
Changes in TB service utilisation (TB testing uptake;
TB case detection rate; the number of new cases of
TB; the number of direct smears processed by labora-
tories; TB treatment adherence rates; retention rates
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and rates of surgical procedures used in TB the diag-
nosis or treatment, etc).
Secondary outcomes
The secondary outcomes include:
Changes in the level of stigma (aspects such as nega-
tive attitudes towards the perceived behaviour of
people with TB and lack of knowledge about TB) and
discrimination against people with TB.
Cost of the intervention.
Objectively measured outcomes data as reported in
included studies will be considered acceptable.
Definitions
In the context of this systematic review, TB service utilisa-
tion is deﬁned broadly to include the use of preventative
or curative TB treatment, TB diagnostic tests and surgi-
cal procedures used in TB diagnosis or treatment.
Search methods for identification of studies
Electronic searches
MDN, with the help of a university librarian, will perform
electronic searches in PubMed, Scopus, Cochrane Central
Register of Controlled Trials (CENTRAL), ISI Web of
Science (Science Citation Index), Africa-Wide Information,
Cumulative Index of Nursing and Allied Health
(CINAHL) and PsycINFO. Table 1 presents the PubMed
search strategy. Slight modiﬁcations of this strategy will be
used for the other databases. Articles written in or trans-
lated into English and French and published from January
1980 (the advent of the new wave of TB infections
related to HIV/AIDS and the subsequent emergence of
drug-resistant TB from the misuse or mismanagement of
anti-TB treatment) to 31 October 2013 will be eligible
for inclusion in this review.
Searching other sources
Manual searches will include scanning the reference lists
of relevant studies, specialist journals and conference
proceedings. Information on unpublished or ongoing
studies will be sought through the WHO International
Clinical Trial Registry Platform, Clinicaltrials.gov, Pan
African Clinical Trials Registry (PACTR) and through
correspondence with experts within the TB ﬁeld. The
websites tb.org and http://www.stoptb.org will be sought
for available material.
Data collection and analysis
The methodology for data collection and analysis will be
based on the guidance of the Cochrane Handbook of
Systematic Reviews for Interventions.13
Selection of studies
A screening form will be created for this review. This
screening form will be piloted to ensure that the inclu-
sion criteria are adhered to and consistently applied by
all review authors. Two review (MDN and CSW) authors
will independently scan search outputs and retrieve
potentially eligible studies using the piloted screening
form. One review author will obtain the full text articles
deemed to be relevant, and MDN and CSW will inde-
pendently assess these for eligibility using the aforemen-
tioned criteria. Then, the studies excluded will be listed
with the reason for exclusion. If disagreements occur
between assessors, they will be resolved through discus-
sion and consensus. If the disagreement persists, a third
author (LGB, RW, MS, OU) will be consulted.
Data extraction and management
A standardised data extraction form will be developed
for this review. We will pilot the form on three studies to
assess its completeness and usability. Two review authors
(MDN and CSW) will independently extract data using
the standardised data extraction form, resolving discrep-
ancies by discussion and consensus. When there is a dif-
ference of opinion, a third review author will be
consulted. MDN will enter the ﬁnal data into Review
Manager V.5.2 statistical software (The Cochrane
Collaboration, Copenhagen, Denmark). CSW will cross-
check the data entered to ensure that there are no data
entry errors.
The following data will be extracted from the included
studies for use in assessing risk of bias.
Characteristics of the study: study setting and location;
and the number of study sites (when applicable), study
design, the method of recruitment of participants and
the funding source.
Patient characteristics: age, sex and ethnicity of the
participants; number of participants.
Characteristics of the intervention: type and duration
of the intervention.
Independent variables that are studied.
Outcome data in the intervention and control group.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias
in each included study. We will use the Cochrane Risk of
Bias tool in the assessment.13 Separate criteria will be
used to assess RCTs and non-randomised studies. For
RCTs, we will assess risk of bias using the following key
criteria: random sequence generation; allocation con-
cealment; blinding of participants and personnel; blind-
ing of outcome assessors; incomplete outcome data;
selective outcome reporting; other sources of bias and
overall risk of bias.13 For non-randomised studies, we will
focus on speciﬁc outcomes of the study (eg, outcomes
assessments) and the extent to which the studies are sus-
ceptible to bias (eg, selection, performance, detection,
attrition and reporting biases) in assessing risk of bias.13
In addition to using the Cochrane risk of bias tool, we
will also use the Newcastle-Ottawa Scale (NOS) to assess
risk of bias in non-randomised studies.14 The NOS pro-
vides criteria for making judgments about risk of bias in
the following areas: selection of study groups, compar-
ability of groups and ascertainment of outcomes (in the
case of cohort studies).14 Therefore, this instrument
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helps to assess the quality of non-randomised studies so
that they can be included in a systematic review.
The risk of bias table available in Review Manager
V.5.2 software (The Cochrane Collaboration,
Copenhagen, Denmark) will need to be operationalised
in order to be used for RCTs and non-randomised
studies (in the case of non-RCTs, CBAs and cohort
studies) according to the aforementioned criteria.13 14
Certain items in the Risk of Bias table, for example,
random sequence generation will not be applicable for
non-randomised studies. Other biases will include four
areas: comparability of cohorts for baseline character-
istics and outcome measures on the basis of design and
analysis; selection of the non-exposed cohort; protection
against contamination and ascertainment of exposure.
For assessing the methodological quality of ITS
studies, we will use the criteria developed by the
Cochrane Effective Practice and Organization of Care
(EPOC) Review Group to assess the risk of bias.15 These
criteria are as follows:
Was the intervention independent of other changes?
Was the shape of the intervention effect prespeciﬁed?
Was the intervention unlikely to affect data collection?
Was knowledge of the allocated interventions adequately
prevented during the study?
Were incomplete outcome data adequately addressed?
Table 1 PubMed search strategy, modified as appropriate for use in other database
No Query
#1 tuberculosis [MeSH]
#2 Tuberculosis [tiab]
#3 #1 OR #2
#4 “mass media” [MeSH] OR “mass media” [tiab]
#5 “health communication” [MeSH] OR “health communication*” [tiab]
#6 communication [MeSH] OR communication* [tiab]
#7 “multimedia” [tiab]
#8 multimedia [tiab]
#9 “mass communication” [tiab]
#10 “audiovisual equipment” [tiab]
#11 “patient information” [tiab]
#12 “visual information” [tiab]
#13 radio [tiab]
#14 television [tiab]
#15 leaflet* [tiab]
#16 poster* [tiab]
#17 pamphlet* [tiab]
#18 “print media” [tiab]
#19 “printed media” [tiab]
#20 skit* [tiab]
#21 “talk show*” [tiab]
#22 broadcast* [tiab]
#23 film* [tiab]
#24 telecommunication* [tiab]
#25 internet [MeSH] OR internet [tiab]
#26 Patient advocacy [MeSH] OR advocacy [tiab] OR “social mobilization” [tiab] OR “ACSM” [tiab]
#27 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26
#28 #27 AND #3
#29 “health behavior” [MeSH] OR “health behavior” [tiab]
#30 “health promotion” [MeSH] OR “health promotion” [tiab]
#31 “health education” [MeSH]] OR “health education” [tiab]
#32 “patient education as topic” [MeSH]
#33 “health knowledge, attitudes, practice” [MeSH] OR knowledge [tiab] OR attitude* [tiab] OR
practice* [tiab]
#34 “awareness” [MeSH] OR “awareness [tiab]
#35 “Health Services/utilization” [MeSH]
#36 “Health Services Research” [MeSH]
#37 “Patient Acceptance of Health Care” [MeSH] OR “health seeking behavior” [tiab]
#38 #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR 35 OR #36 OR #37
#39 #28 AND #38
#40 Humans [MeSH]
#41 #40 AND #39
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Was the study free from selective outcome reporting?
Was the study free from other risks of bias?
Studies will be scored as low, high or unclear risk of
bias. The two authors will resolve disagreements in the
assessment of risk of bias by discussion and consensus,
consulting a third author to resolve any persistent
disagreements.
Measures of treatment effect
The outcomes of interest will be either dichotomous or
continuous. Relative risks will be calculated for dichot-
omous outcomes and mean differences for continuous
outcomes, both with their corresponding 95% CIs.
Assessment of heterogeneity
Clinical heterogeneity will be investigated by examining
the types of participants, interventions and outcomes in
each study. Then, we will pool studies judged to be clin-
ically homogenous. Statistical heterogeneity will be inves-
tigated using the χ2 test of homogeneity and quantiﬁed
using the I2 statistic.16 17 If the study results are found to
be statistically homogeneous (ie, heterogeneity p>0.1),
we will pool them using the ﬁxed-effect meta-analysis.
Otherwise, we will use random-effects meta-analysis. The
grading of recommendations, assessment, development
and education (GRADE) approach will be used to assess
the quality of the body of evidence.18 19 This method
results in the assessment of the quality of the body of evi-
dence as high, moderate, low or very low. The evidence
is considered of high quality if further research is very
unlikely to change our conﬁdence in the estimate of the
effect; and moderate quality if further research is likely
to have an important impact on our conﬁdence in the
estimate of the effect and may change the estimate. The
low-quality evidence implies that further research is
likely to have an important impact on our conﬁdence in
the estimate of the effect and is likely to change the esti-
mate, and very low quality implies that we have very little
conﬁdence in the effect estimate.
Dealing with missing data
Relevant missing data will be sought by contacting the
corresponding authors of included studies. We will use
the last observation carried forward to handle missing
data that cannot be obtained.13
Data analysis
Data analysis will be conducted using Review Manager
V.5.2 statistical software (The Cochrane Collaboration,
Copenhagen, Denmark). Where studies are found to be
clinically and statistically homogeneous, we will pool the
studies in a meta-analysis. For dichotomous outcomes,
we will combine the results and calculate the risk ratio
and 95% CIs. For continuous outcomes that are mea-
sured on the same scale, we will combine the mean dif-
ferences to calculate the mean difference and SD. For
continuous outcomes that are not measured on the
same scale, we will standardise the measurements on a
uniform scale before they can be pooled in a
meta-analysis. Then we will calculate the standardised
mean difference and 95% CIs.
Subgroup analysis
We shall explore stratiﬁcation by the following
subgroups:
Age (children, adolescents, adult or mixed
populations);
Type of mass media intervention;
Study setting (low-income and middle-income coun-
tries vs high-income countries).
These subgroups were chosen because we anticipate
statistical heterogeneity due to anticipated differences
between study populations and interventions. For
example, we anticipate that age will have an impact on
the interpretation of TB-related messages communicated
through mass media. Children and adults are more
likely to positively accept TB messages communicated in
an innovative, fun and engaging manner that promote
internalised decision-making and ultimately inﬂuence
their TB-related behaviour, compared with adults.
Sensitivity analysis
We will conduct sensitivity analyses to assess the effect of
missing data on our primary meta-analyses. When we ﬁnd
a study with missing data, we will ﬁrst perform available
cases analysis, followed by sensitivity analyses according to
imputations (ie, from assuming that all missing data are
failures to assuming that all missing data are successes).
We will also conduct sensitivity analyses to investigate the
robustness of the results to risk of bias (ie, excluding
trials with high risk of bias) and method of meta-analysis
(ie, random-effects vs ﬁxed-effect). For sensitivity analyses,
we will deﬁne ‘high risk of bias’ based on each of three
criteria, namely inadequate concealment of group alloca-
tion, inadequate blinding of outcome assessment and dif-
ferential loss to follow-up (ie, differences in the
proportion of incomplete outcome data across interven-
tion groups, where availability of outcome data is deter-
mined by the participants’ true outcomes).
Ethics and dissemination
The systematic review did not require ethical approval
because the data cannot be linked to an individual. The
ﬁndings of this systematic review will have important
implications for clinical practice and research. The
review will shed light on the potential use of mass media
interventions to promote knowledge, attitudes and opi-
nions about TB and encourage the use of TB services by
those engaged in promoting better uptake of health
information in clinical practice. Future studies may learn
how to create effective media messages about TB, what
is the most effective media platform to use and whether
media messages have different impacts on different
target audiences. The ﬁndings of this systematic review
will be disseminated electronically and in print by peer-
reviewed publication.
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